4 active shortage notices across 2 countries.
Last updated 1 Nov 2026 · sourced from official medicines regulators
Same-class context from the WHO ATC classification only — not a clinical substitution recommendation, not reviewed by a pharmacist, and not dose-equivalent. Form, strength, route and indication may differ. Confirm any switch with a prescriber.
Yes. As of the latest regulator updates, Bimatoprost has 4 active shortage notices across 2 countries (Canada, Italy). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Bimatoprost shortages to manufacturing problems, causes not stated by the regulator. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 15 May 2026 to 15 May 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Mederti lists 1 drug in the same WHO ATC class as Bimatoprost (see above). These are classification context only — not clinically reviewed substitutes. Always confirm any switch with a pharmacist or prescriber and your national guidance.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Dipivefrin Hydrochloride · Dipivefrin · Apraclonidine (Chlorhydrate D') · Apraclonidine Ophthalmic Solution 0.5% · Acetylcholine Chloride · Ach
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.